Where are the phase IIb results for Bimatoprost?

Collapse
X
 
  • Time
  • Show
Clear All
new posts

  • 79BirdofPrey
    replied
    New to this topic - what is the working principle behind Bimatoprost? Is it another DHT blocker?

    Leave a comment:


  • throwaway184
    replied
    close enough that I can get by w/o trying Fin?

    Leave a comment:


  • rdawg
    replied
    Originally posted by It's2014ComeOnAlready
    Allergan is buying Kythera for $2.1 billion. I find this very interesting, given that Kythera's Chief Medical Officer worked at Allergan for over a decade. Also, they announced trials for Setipiprant soon after the phase IIb studies for bimatoprost were complete for Allergan. I'm sure they knew the results, given the company ties. This is very interesting given the mutual reliance on prostaglandin science.

    It looks like Allergan may be trying to corner the hair loss market. Look at this quote in April 2014 from Bosley Medical Director, Ken Washenik:

    " The true Holy Grail may come from combining a drug like Latisse with a certain type of medication commonly used to treat allergies and asthma. The medication blocks a hormone-like substance that prevents hair from growing. A treatment like this might help with hair growth. Using these drugs in combination is like taking your foot off-break and stepping on gas at the same time."

    Looks like Allergan is trying to corner the hair loss market. Sure, nobody wants a double chin either, but if Setipiprant is successful, it would shatter any earnings made by that injectable fat-burning drug. I really hope this means bim was successful, it may mean just that.
    This could come down to the patent thing as well, multiple companies can make the bimatoprost solution can't they?

    but they can't make a combination of these two.

    something big may be brewing behind the scenes here, and neither of these products are too far in the distance.

    Leave a comment:


  • BiqqieSmalls
    replied
    So I guess the Investor Relations woman was right. Why else would Allergan buy $KYTH if they didn't want to use Seti in conjunction with Bim? To whomever said Bim's Phase II had negative results... what now?!

    Leave a comment:


  • Justinian
    replied
    Originally posted by It's2014ComeOnAlready
    " The true Holy Grail may come from combining a drug like Latisse with a certain type of medication commonly used to treat allergies and asthma. The medication blocks a hormone-like substance that prevents hair from growing. A treatment like this might help with hair growth. Using these drugs in combination is like taking your foot off-break and stepping on gas at the same time."
    Very good find. It's very interesting how he mentioned this way back in early 2014.

    Leave a comment:


  • FearTheLoss
    replied
    Originally posted by burtandernie
    I think everyone is curious what using those 2 drugs in combination would do. What kind of results are we talking? Could be minor or huge really impossible to guess. It would be kind of funny to see MPB nearly cured with a combo like this that no one would ever predicted or expected. For all the talk everyone does about millions of things about diet, air pollution, and so on causing MPB it would be odd for something like this to grow back a lot of hair. I guess lots of people turning out to be wrong is not a new thing either.
    That's not true at all, numerous hair loss researchers have stated a combo like this should give great results. PGE2 up and PGD2 down = hair

    Leave a comment:


  • burtandernie
    replied
    I think everyone is curious what using those 2 drugs in combination would do. What kind of results are we talking? Could be minor or huge really impossible to guess. It would be kind of funny to see MPB nearly cured with a combo like this that no one would ever predicted or expected. For all the talk everyone does about millions of things about diet, air pollution, and so on causing MPB it would be odd for something like this to grow back a lot of hair. I guess lots of people turning out to be wrong is not a new thing either.

    Leave a comment:


  • BiqqieSmalls
    replied
    They're definitely trying to capture the whole MPB market share and they will succeed. I am super stoked.

    Leave a comment:


  • It's2014ComeOnAlready
    replied
    Allergan is buying Kythera for $2.1 billion. I find this very interesting, given that Kythera's Chief Medical Officer worked at Allergan for over a decade. Also, they announced trials for Setipiprant soon after the phase IIb studies for bimatoprost were complete for Allergan. I'm sure they knew the results, given the company ties. This is very interesting given the mutual reliance on prostaglandin science.

    It looks like Allergan may be trying to corner the hair loss market. Look at this quote in April 2014 from Bosley Medical Director, Ken Washenik:

    " The true Holy Grail may come from combining a drug like Latisse with a certain type of medication commonly used to treat allergies and asthma. The medication blocks a hormone-like substance that prevents hair from growing. A treatment like this might help with hair growth. Using these drugs in combination is like taking your foot off-break and stepping on gas at the same time."

    Looks like Allergan is trying to corner the hair loss market. Sure, nobody wants a double chin either, but if Setipiprant is successful, it would shatter any earnings made by that injectable fat-burning drug. I really hope this means bim was successful, it may mean just that.

    Leave a comment:


  • FearTheLoss
    replied
    Originally posted by It's2014ComeOnAlready
    Biqqie Smalls is a shareholder, and he contacted investor relations. The person he spoke with said "in a few months," this was last month. So hopefully sometime in August or Sept.

    I'm with you in believing the results are positive. There is no reason for a company of their size to hold back negative results. I would say 1. the results are great and they are keeping it silent because of patent issues and other companies being able to produce bim. 2. the results are good and they are waiting to see how other trials pan out before spending money on a phase III...either way, it will be interesting to see

    Leave a comment:


  • It's2014ComeOnAlready
    replied
    Originally posted by FearTheLoss
    Has anyone got a definitive answer on when these results will, or have to be released? or are we still shooting in the dark?
    Biqqie Smalls is a shareholder, and he contacted investor relations. The person he spoke with said "in a few months," this was last month. So hopefully sometime in August or Sept.

    Leave a comment:


  • FearTheLoss
    replied
    Has anyone got a definitive answer on when these results will, or have to be released? or are we still shooting in the dark?

    Leave a comment:


  • It's2014ComeOnAlready
    replied
    Originally posted by Keki
    ok guys i found some info http://ec.europa.eu/competition/merg...4195749_EN.pdf

    this document explain the "complexity", very interesting let me know what do you thing about this
    Yea it definitely points to an issue with other companies being able to produce bimatoprost. No way to tell if the trial went well, but it does tell us that the issue with this drug is legally complex.

    Just speculating, but if their explanation is that they haven't released results because of these "complexities," then it probably did well. Makes no sense to guard a failure, if overall, there is an issue where other companies can produce the drug themselves. If it didn't work for hair loss, I think we'd know by now. No money to be lost.

    Leave a comment:


  • Keki
    replied
    ok guys i found some info http://ec.europa.eu/competition/merg...4195749_EN.pdf

    this document explain the "complexity", very interesting let me know what do you thing about this

    Leave a comment:


  • Keki
    replied
    If it worked why waste a year? It needs to pe public the eventual phase 3 anyway, so i don't understand, the complexity of bim and their patent issue are easily fixed by one of the top 5-6 pharma company

    Leave a comment:

Working...